pdf

O’Melveny Welcomes Life Sciences Litigator in New York

October 01, 2018

FOR IMMEDIATE RELEASE

NEW YORK—October 1, 2018—O’Melveny announced today that Dr. Hassen A. Sayeed has joined the firm as a partner in its Intellectual Property & Technology Practice Group. Sayeed is an experienced litigator who counsels life sciences companies in all aspects of complex patent litigation. He is one of the few intellectual property lawyers in the United States to hold a medical degree.

Sayeed joins O’Melveny’s New York office from another prominent international law firm where he was a partner in its Intellectual Property practice. In July, O’Melveny added life sciences transactions partner Dr. Geoffrey Kuziemko, who holds a Ph.D. in biophysical chemistry.

Sayeed draws on a deep reservoir of scientific knowledge when framing legal arguments for his clients. He has more than a decade of experience advising leading pharmaceutical companies in cases arising under the Hatch-Waxman Act. Sayeed also has extensive experience in the emerging field of biosimilars patent litigation. He has litigated cases involving a wide range of pharmaceutical, biotechnology, and medical device technologies for companies including AstraZeneca LP, Bayer HealthCare Pharmaceuticals, Inc., Boehringer Ingelheim, Mitsubishi Tanabe Pharma Corporation, Pfizer, Schering Corporation, and Wyeth Pharmaceuticals.

Sayeed began his legal career with Lisa Pensabene, head of O’Melveny’s Life Sciences Litigation practice, when they were both at another firm. “Working with Lisa again is like coming home,” said Sayeed. “The team at O’Melveny shares my philosophy of client service grounded in legal and technical excellence—and many are old friends.”

“We’re excited to welcome Hassen to the firm as we continue to expand our life sciences capabilities to fit our clients’ needs,” said Bradley J. Butwin, chair of O’Melveny. “Few patent lawyers can offer Hassen’s in-depth experience in pharmaceutical and biotech litigation. His arrival gives the O’Melveny team another important advantage and reflects our commitment to life sciences innovation.”

Sayeed has long been involved in the legal community, as a prominent speaker on patent law issues and as a champion of diversity in the IP bar. He earned his J.D. from Harvard Law School, his M.D. from Brown University Medical School, and his B.A. from Harvard University.

Like its clients, O’Melveny’s life sciences patent litigation team is dedicated to following the science. Every member of the team is technically trained, including lawyers with advanced degrees in chemistry, pharmacology, molecular biology, and biology. Firm lawyers have decades of Hatch-Waxman experience and have litigated cases on dozens of innovator drugs from blockbusters to orphan drugs. O’Melveny is a recognized leader in biosimilars litigation and biotechnology patents. The firm’s life sciences lawyers have the support of O’Melveny’s technically experienced Corporate Transactional practice and renowned Litigation practice.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.

Contact:

Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com